Top Page
Prescient Therapeutics Limited
(Sydney:PTX)
Prescient Therapeutics Limited (PTX) vs. S&P 500 (SPY)
Prescient Therapeutics Limited Business Overview & Revenue Model
Prescient Therapeutics Limited Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 3.71M | 2.43M | 1.89M | 1.19M | 1.03M | Gross Profit |
| 3.71M | 2.43M | 1.89M | 1.19M | 1.03M | EBIT |
| -7.19M | -9.89M | -7.10M | -5.43M | -4.49M | EBITDA |
| -7.19M | -7.46M | -5.21M | -4.24M | -3.46M | Net Income Common Stockholders |
| -8.24M | -7.00M | -5.12M | -4.15M | -3.32M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 14.51M | 21.92M | 12.28M | 16.12M | 7.38M | Total Assets |
| 20.39M | 28.11M | 17.62M | 20.97M | 12.07M | Total Debt |
| 330.49K | 0.00 | 0.00 | 165.83K | 156.88K | Net Debt |
| -10.16M | -5.90M | -12.26M | -15.93M | -7.20M | Total Liabilities |
| 2.33M | 2.03M | 856.01K | 539.68K | 883.95K | Stockholders Equity |
| 18.07M | 26.08M | 16.76M | 20.43M | 11.19M |
| Cash Flow | Free Cash Flow | |||
| -7.40M | -6.19M | -4.32M | -3.97M | -2.32M | Operating Cash Flow |
| -7.40M | -6.19M | -4.31M | -3.97M | -2.32M | Investing Cash Flow |
| 12.00M | -16.00M | -4.43K | -2.31K | 0.00 | Financing Cash Flow |
| 18.15K | 15.83M | 428.29K | 12.75M | 0.00 |
Prescient Therapeutics Limited Technical Analysis
Prescient Therapeutics Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$36.24M | ― | -36.95% | ― | ― | 11.11% | |
54 Neutral | AU$202.39M | ― | -37.20% | ― | ― | 32.02% | |
52 Neutral | $5.21B | 3.55 | -41.91% | 2.83% | 15.12% | 0.42% | |
37 Underperform | $179.21M | ― | -99.05% | ― | ― | -34.09% | |
36 Underperform | AU$3.98M | ― | -119.28% | ― | ― | 64.10% | |
30 Underperform | AU$738.77M | ― | ― | -24.46% | -7.90% |
Prescient Therapeutics Limited Corporate Events
Prescient Therapeutics Limited announced a change in the director’s interest, with Melanie Farris acquiring 250,000 fully paid ordinary shares through an on-market trade. This transaction reflects a significant personal investment by a key company leader, potentially indicating confidence in the company’s future prospects and strategic direction.
Prescient Therapeutics has achieved a significant milestone by opening the first clinical site for its PTX-100 Phase 2a study, targeting Cutaneous T-Cell Lymphoma. The company presented new clinical data at an international forum, highlighting PTX-100’s mechanism of action and safety profile. Financially, Prescient reported a cash balance of $10.2 million, bolstered by a $3.7 million R&D Tax Incentive Rebate. The company is also exploring collaborations to enhance cell therapy programs and has appointed Dr. James Campbell as the new Board Chair, succeeding Steven Engle.
Prescient Therapeutics announced an investor briefing to discuss the next phase of their PTX-100 program, following the U.S. FDA’s fast track designation. The company is advancing its oncology pipeline with a planned Phase 2 study for PTX-100 in Cutaneous T cell lymphoma, highlighting its potential impact on cancer treatment and market positioning.
Prescient Therapeutics Limited has received the U.S. FDA Fast Track designation for its PTX-100 drug, aimed at treating relapsed or refractory mycosis fungoides, a subtype of Cutaneous T Cell Lymphoma (CTCL). This designation is a significant milestone, facilitating accelerated approval processes and potentially expediting the drug’s availability to patients. The Fast Track status underscores the FDA’s recognition of PTX-100’s promise in addressing unmet medical needs, enhancing Prescient’s strategic positioning in the oncology market.
Prescient Therapeutics Limited has appointed Melanie Farris as an independent Non-Executive Director and Chair of the Audit and Risk Committee. With over 18 years of experience in life sciences governance and risk management, Farris is expected to bring valuable expertise to the board as the company advances its personalized cancer therapies, including the promising PTX-100, into further clinical trials. Her appointment is seen as a strategic move to strengthen the company’s governance and operational oversight, potentially enhancing stakeholder value as Prescient continues to pursue its mission of improving cancer patient outcomes.
Prescient Therapeutics Limited announced an upcoming investor briefing to discuss the next phase towards the approval and commercialization of PTX-100, a promising cancer therapy. The company is advancing its clinical trials, with a Phase 2 study in Cutaneous T cell lymphoma planned for April 2025, highlighting its commitment to innovative cancer treatments and potential market impact.
Prescient Therapeutics Limited has announced the initiation of its first clinical site for the Phase 2a study of PTX-100, a potential treatment for Cutaneous T-Cell Lymphoma (CTCL). This milestone marks the beginning of a multi-site study across Australia, the USA, and Europe, evaluating the efficacy and safety of PTX-100 in approximately 40 patients. The study’s progress is significant for the company’s operations as it advances its first-in-class therapeutic candidate, potentially impacting its positioning in the oncology market and offering new hope for CTCL patients.
Prescient Therapeutics Limited has appointed Dr. Marissa Lim as the new Chief Medical Officer, succeeding Dr. Terrence Chew. Dr. Lim, with over 20 years of experience in pharmaceutical and biotech sectors, will lead the clinical development of Prescient’s innovative pipeline, including the Phase 2 study of PTX-100 for Cutaneous T cell lymphoma and the advancement of next-generation cell therapy platforms. This leadership change is expected to bolster Prescient’s efforts in advancing personalized cancer treatments, potentially transforming CAR-T therapies and impacting the lives of cancer patients.
Prescient Therapeutics Limited announced a change in the director’s interest, with Dr. Gavin Shepherd acquiring additional shares through an on-market trade. This acquisition reflects a modest increase in Dr. Shepherd’s indirect holdings, potentially signaling confidence in the company’s future prospects and stability in its leadership.
Prescient Therapeutics Limited has announced a change in its Board Chair, with Dr. James Campbell set to succeed Mr. Steven Engle, who is retiring after over a decade in the role. This transition occurs as the company is poised for significant growth, particularly with the initiation of Phase 2 studies for PTX-100, a promising treatment for T Cell Lymphoma. The leadership change is expected to provide continuity and strategic guidance as Prescient advances its clinical programs and strengthens its position in the oncology sector.
Prescient Therapeutics Limited reported a significant decrease in both revenue and losses for the half-year ending December 31, 2024. The company experienced a 48.3% drop in revenue from ordinary activities, while losses after tax decreased by 32.3% compared to the previous period. The reduction in losses is attributed to lower research and development expenses, as well as decreased corporate and administrative costs. The company’s net assets fell, primarily due to changes in trade creditors and an increase in research and development claims receivable. While no dividends were declared, the company received a notable R&D tax incentive, impacting their financial positioning.